New Study Links Fosamax to Vision Problems Risk According to a study published in April 2012 on the Canadian Medical Association Journal (CMAJ) first-time use of oral bisphosphonates (including Fosamax) is associated with greater risk for two inflammatory eye diseases, uveitis and scleritis. Fosamax, manufactured by Merck, was approved by the FDA in 1995 and developed to treat post-menopausal osteoporosis and Paget's disease of bone. On June ... [News Source]